





## Surfactant protein D (SP-D) as a biomarker of SARS-CoV-2 infection

<u>**Testa F.1**</u>, Salvioni L.<sup>1</sup>, Lovaglio P.G.<sup>2</sup>, Berta P.<sup>2</sup>, Leoni V.<sup>3</sup>, Brambilla P.<sup>3</sup>, Prosperi D.<sup>1</sup>, Vittadini G.<sup>2</sup>, Colombo M.<sup>1</sup>, Fiandra L.<sup>1</sup>

E-mail: f.testa@campus.unimib.it

<sup>1</sup> Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, 20126 Milan, Italy

<sup>2</sup> Department of Statistics and Quantitative Methods, University of Milano-Bicocca, University of Milano-Bicocca, Via Bicocca degli Arcimboldi 8, 20126 Milan, Italy

<sup>3</sup> Department of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, 20900 Monza, Italy

Keywords: Sars-CoV-2, Covid-19, SP-D, mortality

## Abstract:

Surfactant protein-D (SP-D) is a lung-resident protein that has emerged as a potential biomarker for COVID-19. Previous investigations on acute respiratory distress syndrome patients demonstrated a significant increment of SP-D serum levels in pathological conditions. Since SP-D is not physiologically permeable to alveoli-capillary membrane and poorly expressed by other tissues, this enhancement is likely due to an impairment of the pulmonary barrier caused by prolonged inflammation.

A retrospective study on a relatively large cohort of patients of Hospital Pio XI of Desio was conducted to assess differences of the hematic SP-D concentrations among COVID-19 patients and healthy donors and if SP-D levels resulted a risk factor for disease severity and mortality.

The first analysis, using an ANOVA-model, showed a significant difference in the mean of log SP-D levels between COVID-19 patients and healthy donors. Significant variations were also found between dead vs survived patients. Results confirm that SP-D concentrations were significantly higher for both hospitalized COVID-19 and dead patients, with threshold values of 150 and 250 ng/mL, respectively. Further analysis conducted with Logistic Mixed models, highlighted that higher SP-D levels at admission and increasing differences among follow-up and admission values resulted the strongest significant risk factors of mortality (model predictive accuracy, AUC = 0.844).

The results indicate that SP-D can be a predictive marker of COVID-19 disease and its outcome. Considering its prognostic value in terms of mortality, the early detection of SP-D levels and its follow-up in hospitalized patients should be considered to direct the therapeutic intervention.